Hauser, Stephen L.; Bar-Or, Amit; Comi, Giancarlo; Correale, Jorge; Coyle, Patricia K.; Cross, Anne H.; de Seze, Jerome; Leppert, David; Montalban, Xavier; Selmaj, Krzysztof; Wiendl, Heinz; Kerloeguen, Cecile; Willi, Roman; Li, Bingbing; Kakarieka, Algirdas; Tomic, Davorka; Goodyear, Alexandra; Pingili, Ratnakar; ASCLEPIOS I and ASCLEPIOS II Trial Groups
(Massachusetts Medical Society, 2020-08-06)
Background: Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of ...